DSM creates a joint venture with Nenter & Co to manufacture vitamin E
Category: #business  By Nikita Chaurasia  Date: 2019-01-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

DSM creates a joint venture with Nenter & Co to manufacture vitamin E
  • DSM is likely to acquire a 75 percent stake in the joint venture for about €135 million.
     
  • The new business will exclusively manufacture vitamin E for DSM

The Dutch nutrition firm DSM has reportedly announced that it is planning to form a joint venture with China’s Nenter & Co., Inc. As per trusted sources, DSM is likely to acquire 75 percent stake in the joint venture for about €135 million.

Reportedly, the joint venture will also include all Nenter’s production and related assets for vitamin E. Moreover, both the firms would refurbish and upgrade the facilities to secure a sustainable and supply of vitamin E.

Sources familiar with the development claim that the venture will have a minority shareholding in Nenter’s Shishou facility in Hubei and will acquire and operate vitamin E manufacturing facilities in Jingzhou, China. Reportedly, there will be a profit share deal in place between Nenter and the Heerlen-headquartered firm and the new joint venture would manufacture vitamin E exclusively for DSM.

According to a press release by DSM, Vitamin E has been well-recognized and accepted as nature’s most effective chain-breaking, fat-soluble antioxidant, safeguarding cellular membranes from being damaged by lipid peroxyl radicals. The statement further noted that vitamin E maintains the structural integrity of all tissues and contributes substantially to optimum health. Apart from being an efficacious biological antioxidant, it also contributes to disease resistance of farm animals owing to modulating effects on the immune system.

For the record, DSM currently manufactures vitamin E in Switzerland and the joint venture will reportedly allow the company to simplify its supply chain by expanding manufacturing to the Asia Pacific region.

Reportedly, the joint venture agreement is expected to conclude in the second or third quarter of 2019, subject to several regulatory approvals.

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia    

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More

More News By Nikita Chaurasia

GSK, Zymeworks expand partnership for bispecific antibody development
GSK, Zymeworks expand partnership for bispecific antibody development
By Nikita Chaurasia

GSK anticipates using Zymeworks’ Azymetric technology for developing bispecifics drugs that treat communicable diseases Zymeworks Inc, a clinical-stage biopharmaceutical company, has recently announced that GSK has extended its 2016 licensing ...

Vertex, Kymera join forces for developing protein degradation drugs
Vertex, Kymera join forces for developing protein degradation drugs
By Nikita Chaurasia

Vertex would be paying $70 million in advance to work with Kymera including an equity investment in the company Kymera Therapeutics and Vertex Pharmaceuticals Incorporated (VRTX) have reportedly announced that they are entering into a four-year rese...

Amazon plans job cuts as it deploys machines to pack orders
Amazon plans job cuts as it deploys machines to pack orders
By Nikita Chaurasia

Amazon is well known for its drive to automate as many segments of its business as possible. The American multinational technology company Amazon Inc. is reportedly planning to deploy machines to automate boxing up customer orders. The company has i...